FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies

Wenyue Shen; Quanwei Zhou; Chenxi Peng; Jiaheng Li; Qizhi Yuan; Hecheng Zhu; Ming Zhao; Xingjun Jiang; Weidong Liu; Caiping Ren

doi:10.3389/fonc.2022.880077

FBXW7 and the Hallmarks of Cancer: Underlying Mechanisms and Prospective Strategies

Front Oncol. 2022 Apr 19:12:880077. doi: 10.3389/fonc.2022.880077. eCollection 2022.

Authors

Wenyue Shen^{1

2}, Quanwei Zhou^{1

2}, Chenxi Peng^{1

2}, Jiaheng Li^{1

2}, Qizhi Yuan^{1

2}, Hecheng Zhu^{3

4}, Ming Zhao⁴, Xingjun Jiang^{1

2}, Weidong Liu^{3

5}, Caiping Ren^{1

2

3

5}

Affiliations

¹ Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China.
² National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.
³ Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, China.
⁴ Changsha Kexin Cancer Hospital, Changsha, China.
⁵ The Key Laboratory of Carcinogenesis of the Chinese Ministry of Health and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medicine, Central South University, Changsha, China.

Abstract

FBXW7, a member of the F-box protein family within the ubiquitin-proteasome system, performs an indispensable role in orchestrating cellular processes through ubiquitination and degradation of its substrates, such as c-MYC, mTOR, MCL-1, Notch, and cyclin E. Mainly functioning as a tumor suppressor, inactivation of FBXW7 induces the aberrations of its downstream pathway, resulting in the occurrence of diseases especially tumorigenesis. Here, we decipher the relationship between FBXW7 and the hallmarks of cancer and discuss the underlying mechanisms. Considering the interplay of cancer hallmarks, we propose several prospective strategies for circumventing the deficits of therapeutic resistance and complete cure of cancer patients.

Keywords: FBXW7; c-MYC; hallmarks of cancer; mTOR; metabolic reprogramming; therapeutic resistance.

Publication types

Review